Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir

Journal of Infectious Diseases

Volumn 180, Issue 6, 1999, Pages 1827-1832

  Lori, Franco ^a,b,f   Jessen, Heiko ^c   Lieberman, Judy ^d   Finzi, Diana ^e   Rosenberg, Eric ^d   Tinelli, Carmine ^b   Walker, Bruce ^d   Siliciano, Robert F ^e   Lisziewicz, Julianna ^a,b  

^a Research Institute for Genetic Human Therapy   (United States)

^b Istituto di Ricovero e Cura a Carattere Scientifico di Diritto Pubblico   (Italy)

^c Jessen Praxis   (Germany)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f RIGHT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; HYDROXYUREA; INDINAVIR; PROTEINASE INHIBITOR;

ARTICLE; CELL LOSS; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOBLOTTING; MALE; PRIORITY JOURNAL; SEROCONVERSION; T LYMPHOCYTE SUBPOPULATION; VIRUS LOAD;

ANTI-HIV AGENTS; BLOTTING, WESTERN; CD4 LYMPHOCYTE COUNT; CD4-CD8 RATIO; CD8-POSITIVE T-LYMPHOCYTES; DIDANOSINE; DRUG THERAPY, COMBINATION; FLOW CYTOMETRY; HIV ANTIBODIES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; HYDROXYUREA; INDINAVIR; LYMPHOCYTE ACTIVATION; VIRAL LOAD;

EID: 0032710328     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315113     Document Type: Article

References (33)

1. + T cell responses associated with control of viremia. Science 1997; 278:1447-50.
2. 2. Lisziewicz J, Jessen H, Finzi D, Siliciano RF, Lori F. HIV-1 suppression by early treatment with hydroxyurea, didanosine, and a protease inhibitor. Lancet 1998; 352: 199-200.
3. + T-cell renewal in early HIV-1 infection: effect of highly active antiretroviral therapy. Nat Med 1998; 4:794-801.
4. 4. Lori F, Jessen H, Lieberman J, Clerici M, Tinelli C, Lisziewicz J. Immune restoration by combination of a cytostatic drug (hydroxyurea) and anti-HIV drugs (didanosine and indinavir). AIDS Res Hum Retroviruses 1999; 15:619-24.
5. +) T cells during primary HIV-1 infection. Proc Natl Acad Sci USA 1998; 95:8869-73.
6. 6. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278:1295-300.
7. 7. Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 1997;94:13193-7.
8. 8. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997; 278: 1291-5.
9. 9. Zhu T, Mo H, Wang N, et al. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 1993;261:1179-81.
10. 10. van't Wout AB, Kootstra NA, Mulder-Kampinga GA, et al. Macrophagetropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission. J Clin Invest 1994; 94: 2060-7.
11. 11. Reinhardt PP, Reinhardt B, Lathey JL, Spector SA. Human cord blood mononuclear cells are preferentially infected by non-syncytium-inducing, macrophage-tropic human immunodeficiency virus type 1 isolates. J Clin Microbiol 1995; 33:292-7.
12. 12. Cameron PU, Lowe MG, Sotzik F, Coughlan AF, Crowe SM, Shortman K. The interaction of macrophage and non-macrophage tropic isolates of HIV-1 with thymic and tonsillar dendritic cells in vitro. J Exp Med 1996; 183:1851-6.
13. 13. Perno CF, Yarchoan R, Cooney DA, et al. Replication of human immunodeficiency virus in monocytes: granulocyte/macrophage colony-stimulating factor (GM-CSF) potentiates viral production yet enhances the antiviral effect mediated by 3′-azido-2′3′-dideoxythymidine (AZT) and other dideoxynucleoside congeners of thymidine. J Exp Med 1989; 169: 933-51.
14. 14. Lori F, Malykh A, Cara A, et al. Hydroxyurea as an inhibitor of human immunodeficiency virus type 1 replication. Science 1994; 266:801-5.
15. + T cell homeostasis and function in advanced HIV disease. Science 1997; 277:112-6.
16. 16. Hellerstein M, Hanley MB, Cesar D, et al. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. Nat Med 1999; 5:83-9.
17. 17. Douek DC, McFarland RD, Keiser PH, et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 1998; 396: 690-5.
18. 18. Pantaleo G. Unraveling the strands of HIV's web. Nat Med 1999; 5:27-8.
19. 19. Roederer M. Getting to the HAART of T cell dynamics. Nat Med 1998; 4: 145-6.
20. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999; 5:512-7.
21. 21. Plana M, Garcia F, Gallart T, Miro JM, Gatell JM. Lack of T-cell proliferative response to HIV-1 antigens after 1 year of highly active antiretroviral treatment in early HIV-1 disease: Immunology Study Group of Spanish EARTH-1 Study. Lancet 1998; 352:1194-5.
22. + T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat Med 1999; 5:518-25.
23. 23. Lori F, Rosenberg E, Lieberman J, et al. Hydroxyurea and didanosine long-term treatment prevents HIV breakthrough and normalizes immune parameters. AIDS Res Hum Retroviruses 1999; 15:1333-8.
24. 24. Lori F, Malykh AG, Foli A, et al. Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance. AIDS Res Hum Retroviruses 1997; 13:1403-9.
25. 25. Rutschmann OT, Opravil M, Iten A, et al. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection: the Swiss HIV Cohort Study. AIDS 1998; 12:F71-7.
26. 26. Zagury D, Bernard J, Leonard R, et al. Long-term cultures of HTLV-III-infected T cells: a model of cytopathology of T-cell depletion in AIDS. Science 1986; 231:850-3.
27. 27. Zack JA, Arrigo SJ, Weitsman SR, Go AS, Haislip A, Chen IS. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 1990; 61:213-22.
28. 28. Bukrinsky MI, Stanwick TL, Dempsey MP, Stevenson M. Quiescent T lymphocytes as an inducible virus reservoir in HTV-1 infection. Science 1991;254:423-7.
29. + T cell turnover. Science 1996;274:1543-7.
30. 30. Zinkernagel RM, Hengartner H. HIV: games that viruses play. Nature 1991; 354:433-4.
31. 31. Zinkernagel RM, Hengartner H. Virally induced immunosuppression. Curr Opin Immunol 1992; 4:408-12.
32. 32. Vila J, Nugier F, Bargues G, et al. Absence of viral rebound after treatment of HIV-infected patients with didanosine and hydroxycarbamide. Lancet 1997; 350:635-6.
33. 33. Lisziewicz J, Rosenberg E, Lieberman J, et al. Control of HIV despite the discontinuation of antiretroviral therapy. N Engl J Med 1999; 340:1683-4.